Data were collected locally and centralised. Putative predictors included 18 pretherapeutic clinicopathological and Ga-PSMA-11 PET/CT variables. Eligible patients had received intravenous 6♰–8♵ GBq 177Lu-PSMA once every 6–8 weeks, for a maximum of four to six cycles, and had available baseline Ga-PSMA-11 PET/CT scan, clinical data, and survival outcomes. In this multicentre, retrospective study, we screened patients with mCRPC who had received 177Lu-PSMA between Dec 10, 2014, and July 19, 2019, as part of the previous phase 2 trials ( NCT03042312, ACTRN12615000912583) or compassionate access programmes at six hospitals and academic centres in Germany, the USA, and Australia. Advancing women in science, medicine and global health.
0 Comments
Leave a Reply. |